Compare BNR & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | NYXH |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.9M | 188.1M |
| IPO Year | 2020 | 2021 |
| Metric | BNR | NYXH |
|---|---|---|
| Price | $35.50 | $4.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 34.1K | ★ 50.6K |
| Earning Date | 11-20-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,749,382.00 | $6,616,215.00 |
| Revenue This Year | $136.32 | $75.27 |
| Revenue Next Year | N/A | $277.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.56 | ★ 10.96 |
| 52 Week Low | $2.18 | $4.35 |
| 52 Week High | $41.72 | $11.87 |
| Indicator | BNR | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 49.67 |
| Support Level | $35.00 | $4.70 |
| Resistance Level | $41.72 | $5.00 |
| Average True Range (ATR) | 3.51 | 0.22 |
| MACD | 0.75 | -0.02 |
| Stochastic Oscillator | 76.55 | 26.71 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.